P222: Continuous Innovation and Transformation Amidst Organizational and Regulatory Complexities
Poster Presenter
Aarti Sharma
Director of Strategic Priorities and Initiatives
AbbVie United States
Objectives
Offers: unique insights on multi-faceted complexities and ambiguities (global/local) confronting global biopharma companies seeking transformational therapies; guidance on cross-functional strategies for innovation, organizational development and regulatory excellence for successful transformations
Method
This thought-leadership poster draws on author’s Ph.D., her publications in refereed and industry journals, and 20 years of multi-disciplinary industry and academic experiences in strategy, public policy, organizational behavior, stakeholder engagement, global business transformation management
Results
The poster is based on author’s Ph.D. research that used critical-interpretive methodology and techniques, including analyses of qualitative interviews, organizational and national leaders’ dialogues, ethnographic notes, regulations, organizational as well as policy documents. The research investigated stakeholder engagement strategies and partnerships, amidst complex societal challenges and global regulatory changes, required for sustainable innovations. The insights from the Ph.D. research were further utilized by the author to validate and advance the application of her academic and practical knowledge in various organizational settings, as a part of the author’s industry experience, including within biopharma and management consulting industries.
Conclusion
Author’s academic and practical findings indicate a complex interplay of internal and external forces, including patients’ needs, competitive pressures, regulatory demands and shareholders’ expectations, are at play. Those dynamic forces pressure and fuel biopharma companies’ desire and drive for innovation, globally and locally. Those forces further compel demands and cycles of transformations within the companies—transformations in business model, organizational structures and designs, external and internal partnerships, and regulatory capabilities to deal with complexities.
Author finds that companies that are innovating to solve complex problems not only for themselves and their shareholders, but for their ecosystem of stakeholders are the ones that are truly successful and sustainable in the long run. The poster yields insights into what those stakeholder engagement strategies should look like for biopharma companies attempting to innovate and transform themselves, sustainably.
